4.1 Review

Neuroimaging in Dementia

期刊

SEMINARS IN NEUROLOGY
卷 28, 期 4, 页码 467-483

出版社

THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0028-1083695

关键词

MRI; PET; Pittsburgh Compound-B; dementia; neurodegenerative disease

资金

  1. NIA [K23AG021989]
  2. NIH-NIA [1P01 AG021601]
  3. Fondazione Tronchetti-Provera, Milan, Italy
  4. NATIONAL INSTITUTE ON AGING [K23AG021989, P01AG021601] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Although dementia is a clinical diagnosis, neuroimaging often is crucial for proper assessment. Magnetic resonance imaging (MRI) and computed tomography (CT) may identify nondegenerative and potentially treatable causes of dementia. Recent neuroimaging advances, such as the Pittsburgh Compound-B (PIB) ligand for positron emission tomography imaging in Alzheimer's disease, will improve our ability to differentiate among the neurodegenerative dementias. High-resolution volumetric MRI has increased the capacity to identify the various forms of the frontotemporal lobar degeneration spectrum and some forms of parkinsonism or cerebellar neurodegenerative disorders, such as corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, and spinocerebellar ataxias. In many cases, the specific pattern of cortical and subcortical abnormalities on MRI has diagnostic utility. Finally, among the new MRI methods, diffusion-weighted MRI can help in the early diagnosis of Creutzfeldt-Jakob disease. Although only clinical assessment can lead to a diagnosis of dementia, neuroimaging is clearly an invaluable tool for the clinician in the differential diagnosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据